The U.S. Food and Drug Administration (USFDA) has completed inspection at Natco Pharma’s Finished Dosage Formulations (FDF) manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India. USFDA has conducted inspection from August 17, 2026- August 21, 2026.
Upon conclusion of the inspection, the company has been issued a Form 483 with 4 (Four) observations. The observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines.
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
